8 completed, 1 terminated, 1 unknown. 10 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 8, Terminated 1, Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow mavrilimumab: new trials by email Literature Review of mavrilimumab trials Research Report on mavrilimumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation Mavrilimumab, Placebos - COVID-19, Sars-CoV2 | Phase 2 | Completed | Virginia Commonwealth University | 2 | 2020-09-02 | 2021-08-11 |
| Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation mavrilimumab, Placebo - COVID | Phase 2 / Phase 3 | Completed | Kiniksa Pharmaceuticals International, plc | 814 | 2020-07-28 | 2025-01-22 |
| Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19) Mavrilimumab, Placebo - Covid-19, Acute Respiratory Failure | Phase 2 | Unknown | Ospedale San Raffaele | 50 | 2020-05-22 | 2020-05-26 |
| Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation Mavrilimumab, Placebo - COVID 19, SARS-CoV 2 | Phase 2 | Completed | Kristin Hudock | 1 | 2020-05-20 | 2024-12-09 |
| Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation Mavrilimumab, Placebos - COVID 19, SARS-CoV 2 | Phase 2 | Completed | The Cleveland Clinic | 40 | 2020-05-20 | 2021-05-13 |
| KPL-301 for Subjects With Giant Cell Arteritis mavrilimumab, placebo, prednisone - Giant Cell Arteritis | Phase 2 | Completed | Kiniksa Pharmaceuticals, Ltd. | 70 | 2018-09-20 | 2023-10-23 |
| A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis Golimumab 50 mg, Mavrilimumab 100 mg - Rheumatoid Arthritis | Phase 2 | Completed | MedImmune LLC | 215 | 2013-03-01 | 2016-10-31 |
| A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis Mavrilimumab 100 mg - Rheumatoid Arthritis | Phase 2 | Terminated | MedImmune LLC | 409 | 2013-01-28 | 2017-06-01 |
| A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis Mavrilimumab 30 mg, Mavrilimumab 100 mg, Mavrilimumab 150 mg - Rheumatoid Arthritis | Phase 2 | Completed | MedImmune LLC | 420 | 2012-08-01 | 2016-09-27 |
| A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis Mavrilimumab 10 mg, Mavrilimumab 30 mg, Mavrilimumab 50 mg - Rheumatoid Arthritis | Phase 2 | Completed | MedImmune LLC | 516 | 2010-01-05 | 2018-06-25 |
COVID-19 (5) · Arthritis, Rheumatoid (4) · Pneumonia (4) · Giant Cell Arteritis (1) · Pneumonia, Viral (1) · Respiratory Distress Syndrome (1)
MedImmune LLC (4) · Kiniksa Pharmaceuticals International, plc (1) · Kiniksa Pharmaceuticals, Ltd. (1) · Kristin Hudock (1) · Ospedale San Raffaele (1) · The Cleveland Clinic (1) · Virginia Commonwealth University (1)
United States (5) · Czechia (4) · Estonia (4) · Hungary (4) · Poland (4) · Russia (4) · Serbia (4) · Spain (4) · Argentina (3) · Bulgaria (3) · Chile (3) · Colombia (3) · Germany (3) · South Africa (3) · Ukraine (3)
Marius Albulescu (2) · Antonio Abbate, MD, PhD (1) · John Paolini, M.D. (1) · Kristin Hudock, MD (1) · Lorenzo Dagna, MD (1) · Marius Albulescu, MD (1) · Paul C Cremer, M. D. (1)